Epoetin‐associated pure red cell aplasia: past, present, and future considerations
Identifieur interne : 008830 ( Main/Exploration ); précédent : 008829; suivant : 008831Epoetin‐associated pure red cell aplasia: past, present, and future considerations
Auteurs : June M. Mckoy [France] ; Robin E. Stonecash [France] ; Denis Cournoyer [France] ; Jerome Rossert [France] ; Allen R. Nissenson [France] ; Dennis W. Raisch [France] ; Nicole Casadevall [France] ; Charles L. Bennett [France]Source :
- Transfusion [ 0041-1132 ] ; 2008-08.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : Singapour.
English descriptors
- KwdEn :
- Academic investigators, Academic researchers, Adverse drug events, Alfa, Amgen, Antierythropoietin, Antierythropoietin antibodies, Aplasia, Assay, August, Beta, Canadian prca focus group, Casadevall, Cell aplasia, Chronic kidney disease, Chronic kidney disease patients, Class effect, Darbepoetin, Dial, Epoetin, Epoetin alfa, Epoetin beta, Epoetin products, Epogen, Eprex, Eprex formulation, Erythroblast, Erythropoietin, European medicines agency, Health canada, Hematologic recovery, Hemodialysis, Hemodialysis patients, Immunosuppressive, Immunosuppressive therapy, Incidence rates, Johnson johnson, Kidney disease patients, Leachates, Mckoy, Ndings, Nephrol, Nephrol dial transplant, Neutralizing, Neutralizing antibodies, Other countries, Polysorbate, Prca, Prca cases, Prca patients, Pure aplasia, Pure red cell aplasia, Radar group, Rare instances, Recombinant, Regulatory approval, Regulatory authorities, Roche, Rossert, Severe anemia, Singapore, Stopper, Subcutaneous, Subcutaneous administration, Subcutaneous eprex, Syringe, Transfusion, Transfusion volume, Transplant, Uncoated, Uncoated rubber stoppers.
- Teeft :
- Academic investigators, Academic researchers, Adverse drug events, Alfa, Amgen, Antierythropoietin, Antierythropoietin antibodies, Aplasia, Assay, August, Beta, Canadian prca focus group, Casadevall, Cell aplasia, Chronic kidney disease, Chronic kidney disease patients, Class effect, Darbepoetin, Dial, Epoetin, Epoetin alfa, Epoetin beta, Epoetin products, Epogen, Eprex, Eprex formulation, Erythropoietin, European medicines agency, Health canada, Hematologic recovery, Hemodialysis, Hemodialysis patients, Immunosuppressive, Immunosuppressive therapy, Incidence rates, Johnson johnson, Kidney disease patients, Leachates, Mckoy, Ndings, Nephrol, Nephrol dial transplant, Neutralizing, Neutralizing antibodies, Other countries, Polysorbate, Prca, Prca cases, Prca patients, Pure aplasia, Radar group, Rare instances, Recombinant, Regulatory approval, Regulatory authorities, Roche, Rossert, Severe anemia, Singapore, Stopper, Subcutaneous, Subcutaneous administration, Subcutaneous eprex, Syringe, Transfusion, Transfusion volume, Transplant, Uncoated, Uncoated rubber stoppers.
Abstract
BACKGROUND: Since 1988, millions of patients have received epoetin products intravenously (IV) and subcutaneously. In 1998, epoetin‐associated pure red cell aplasia (PRCA) was first reported and causation was attributed to formulations without human serum albumin (HSA), subcutaneous administration, and uncoated rubber stoppers.
Url:
- https://api.istex.fr/document/62C8628A4EF21823C8B13711A62B018C7EA8D332/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730535
DOI: 10.1111/j.1537-2995.2008.01749.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001256
- to stream Istex, to step Curation: 001256
- to stream Istex, to step Checkpoint: 001197
- to stream Pmc, to step Corpus: 001418
- to stream Pmc, to step Curation: 001278
- to stream Pmc, to step Checkpoint: 002A10
- to stream Ncbi, to step Merge: 000389
- to stream Ncbi, to step Curation: 000389
- to stream Ncbi, to step Checkpoint: 000389
- to stream Main, to step Merge: 009091
- to stream PascalFrancis, to step Corpus: 003375
- to stream PascalFrancis, to step Curation: 002C77
- to stream PascalFrancis, to step Checkpoint: 003263
- to stream Main, to step Merge: 009677
- to stream Main, to step Curation: 008830
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Epoetin‐associated pure red cell aplasia: past, present, and future considerations</title><author><name sortKey="Mckoy, June M" sort="Mckoy, June M" uniqKey="Mckoy J" first="June M." last="Mckoy">June M. Mckoy</name></author><author><name sortKey="Stonecash, Robin E" sort="Stonecash, Robin E" uniqKey="Stonecash R" first="Robin E." last="Stonecash">Robin E. Stonecash</name></author><author><name sortKey="Cournoyer, Denis" sort="Cournoyer, Denis" uniqKey="Cournoyer D" first="Denis" last="Cournoyer">Denis Cournoyer</name></author><author><name sortKey="Rossert, Jerome" sort="Rossert, Jerome" uniqKey="Rossert J" first="Jerome" last="Rossert">Jerome Rossert</name></author><author><name sortKey="Nissenson, Allen R" sort="Nissenson, Allen R" uniqKey="Nissenson A" first="Allen R." last="Nissenson">Allen R. Nissenson</name></author><author><name sortKey="Raisch, Dennis W" sort="Raisch, Dennis W" uniqKey="Raisch D" first="Dennis W." last="Raisch">Dennis W. Raisch</name></author><author><name sortKey="Casadevall, Nicole" sort="Casadevall, Nicole" uniqKey="Casadevall N" first="Nicole" last="Casadevall">Nicole Casadevall</name></author><author><name sortKey="Bennett, Charles L" sort="Bennett, Charles L" uniqKey="Bennett C" first="Charles L." last="Bennett">Charles L. Bennett</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:62C8628A4EF21823C8B13711A62B018C7EA8D332</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1537-2995.2008.01749.x</idno><idno type="url">https://api.istex.fr/document/62C8628A4EF21823C8B13711A62B018C7EA8D332/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001256</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001256</idno><idno type="wicri:Area/Istex/Curation">001256</idno><idno type="wicri:Area/Istex/Checkpoint">001197</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001197</idno><idno type="wicri:doubleKey">0041-1132:2008:Mckoy J:epoetin:associated:pure</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730535</idno><idno type="RBID">PMC:2730535</idno><idno type="wicri:Area/Pmc/Corpus">001418</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001418</idno><idno type="wicri:Area/Pmc/Curation">001278</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001278</idno><idno type="wicri:Area/Pmc/Checkpoint">002A10</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002A10</idno><idno type="wicri:Area/Ncbi/Merge">000389</idno><idno type="wicri:Area/Ncbi/Curation">000389</idno><idno type="wicri:Area/Ncbi/Checkpoint">000389</idno><idno type="wicri:doubleKey">0041-1132:2008:Mckoy J:epoetin:associated:pure</idno><idno type="wicri:Area/Main/Merge">009091</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0388317</idno><idno type="wicri:Area/PascalFrancis/Corpus">003375</idno><idno type="wicri:Area/PascalFrancis/Curation">002C77</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003263</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003263</idno><idno type="wicri:doubleKey">0041-1132:2008:Mckoy J:epoetin:associated:pure</idno><idno type="wicri:Area/Main/Merge">009677</idno><idno type="wicri:Area/Main/Curation">008830</idno><idno type="wicri:Area/Main/Exploration">008830</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Epoetin‐associated pure red cell aplasia: past, present, and future considerations</title><author><name sortKey="Mckoy, June M" sort="Mckoy, June M" uniqKey="Mckoy J" first="June M." last="Mckoy">June M. Mckoy</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>From the Divisions of Hematology/Oncology and Geriatric Medicine of the Department of Medicine, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; the Australian Graduate School of Management, University of New South Wales and the University of Sydney, Sydney, Australia; the Department of Nephrology, Tenon Hospital and Pierre and Marie Curie University, Paris, France; the Departments of Medicine and Oncology, McGill University Health Center, Montreal, Quebec, Canada; the University of New Mexico, VA Cooperative Studies Program, Albuquerque, New Mexico; the Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, California; and Hotel Dieu Hospital and INSERM U362, Department of Hematology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Stonecash, Robin E" sort="Stonecash, Robin E" uniqKey="Stonecash R" first="Robin E." last="Stonecash">Robin E. Stonecash</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>From the Divisions of Hematology/Oncology and Geriatric Medicine of the Department of Medicine, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; the Australian Graduate School of Management, University of New South Wales and the University of Sydney, Sydney, Australia; the Department of Nephrology, Tenon Hospital and Pierre and Marie Curie University, Paris, France; the Departments of Medicine and Oncology, McGill University Health Center, Montreal, Quebec, Canada; the University of New Mexico, VA Cooperative Studies Program, Albuquerque, New Mexico; the Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, California; and Hotel Dieu Hospital and INSERM U362, Department of Hematology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Cournoyer, Denis" sort="Cournoyer, Denis" uniqKey="Cournoyer D" first="Denis" last="Cournoyer">Denis Cournoyer</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>From the Divisions of Hematology/Oncology and Geriatric Medicine of the Department of Medicine, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; the Australian Graduate School of Management, University of New South Wales and the University of Sydney, Sydney, Australia; the Department of Nephrology, Tenon Hospital and Pierre and Marie Curie University, Paris, France; the Departments of Medicine and Oncology, McGill University Health Center, Montreal, Quebec, Canada; the University of New Mexico, VA Cooperative Studies Program, Albuquerque, New Mexico; the Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, California; and Hotel Dieu Hospital and INSERM U362, Department of Hematology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Rossert, Jerome" sort="Rossert, Jerome" uniqKey="Rossert J" first="Jerome" last="Rossert">Jerome Rossert</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>From the Divisions of Hematology/Oncology and Geriatric Medicine of the Department of Medicine, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; the Australian Graduate School of Management, University of New South Wales and the University of Sydney, Sydney, Australia; the Department of Nephrology, Tenon Hospital and Pierre and Marie Curie University, Paris, France; the Departments of Medicine and Oncology, McGill University Health Center, Montreal, Quebec, Canada; the University of New Mexico, VA Cooperative Studies Program, Albuquerque, New Mexico; the Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, California; and Hotel Dieu Hospital and INSERM U362, Department of Hematology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Nissenson, Allen R" sort="Nissenson, Allen R" uniqKey="Nissenson A" first="Allen R." last="Nissenson">Allen R. Nissenson</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>From the Divisions of Hematology/Oncology and Geriatric Medicine of the Department of Medicine, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; the Australian Graduate School of Management, University of New South Wales and the University of Sydney, Sydney, Australia; the Department of Nephrology, Tenon Hospital and Pierre and Marie Curie University, Paris, France; the Departments of Medicine and Oncology, McGill University Health Center, Montreal, Quebec, Canada; the University of New Mexico, VA Cooperative Studies Program, Albuquerque, New Mexico; the Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, California; and Hotel Dieu Hospital and INSERM U362, Department of Hematology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Raisch, Dennis W" sort="Raisch, Dennis W" uniqKey="Raisch D" first="Dennis W." last="Raisch">Dennis W. Raisch</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>From the Divisions of Hematology/Oncology and Geriatric Medicine of the Department of Medicine, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; the Australian Graduate School of Management, University of New South Wales and the University of Sydney, Sydney, Australia; the Department of Nephrology, Tenon Hospital and Pierre and Marie Curie University, Paris, France; the Departments of Medicine and Oncology, McGill University Health Center, Montreal, Quebec, Canada; the University of New Mexico, VA Cooperative Studies Program, Albuquerque, New Mexico; the Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, California; and Hotel Dieu Hospital and INSERM U362, Department of Hematology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Casadevall, Nicole" sort="Casadevall, Nicole" uniqKey="Casadevall N" first="Nicole" last="Casadevall">Nicole Casadevall</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>From the Divisions of Hematology/Oncology and Geriatric Medicine of the Department of Medicine, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; the Australian Graduate School of Management, University of New South Wales and the University of Sydney, Sydney, Australia; the Department of Nephrology, Tenon Hospital and Pierre and Marie Curie University, Paris, France; the Departments of Medicine and Oncology, McGill University Health Center, Montreal, Quebec, Canada; the University of New Mexico, VA Cooperative Studies Program, Albuquerque, New Mexico; the Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, California; and Hotel Dieu Hospital and INSERM U362, Department of Hematology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bennett, Charles L" sort="Bennett, Charles L" uniqKey="Bennett C" first="Charles L." last="Bennett">Charles L. Bennett</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>From the Divisions of Hematology/Oncology and Geriatric Medicine of the Department of Medicine, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; the Australian Graduate School of Management, University of New South Wales and the University of Sydney, Sydney, Australia; the Department of Nephrology, Tenon Hospital and Pierre and Marie Curie University, Paris, France; the Departments of Medicine and Oncology, McGill University Health Center, Montreal, Quebec, Canada; the University of New Mexico, VA Cooperative Studies Program, Albuquerque, New Mexico; the Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, California; and Hotel Dieu Hospital and INSERM U362, Department of Hematology, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Transfusion</title><title level="j" type="alt">TRANSFUSION</title><idno type="ISSN">0041-1132</idno><idno type="eISSN">1537-2995</idno><imprint><biblScope unit="vol">48</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1754">1754</biblScope><biblScope unit="page" to="1762">1762</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2008-08">2008-08</date></imprint><idno type="ISSN">0041-1132</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0041-1132</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Academic investigators</term><term>Academic researchers</term><term>Adverse drug events</term><term>Alfa</term><term>Amgen</term><term>Antierythropoietin</term><term>Antierythropoietin antibodies</term><term>Aplasia</term><term>Assay</term><term>August</term><term>Beta</term><term>Canadian prca focus group</term><term>Casadevall</term><term>Cell aplasia</term><term>Chronic kidney disease</term><term>Chronic kidney disease patients</term><term>Class effect</term><term>Darbepoetin</term><term>Dial</term><term>Epoetin</term><term>Epoetin alfa</term><term>Epoetin beta</term><term>Epoetin products</term><term>Epogen</term><term>Eprex</term><term>Eprex formulation</term><term>Erythroblast</term><term>Erythropoietin</term><term>European medicines agency</term><term>Health canada</term><term>Hematologic recovery</term><term>Hemodialysis</term><term>Hemodialysis patients</term><term>Immunosuppressive</term><term>Immunosuppressive therapy</term><term>Incidence rates</term><term>Johnson johnson</term><term>Kidney disease patients</term><term>Leachates</term><term>Mckoy</term><term>Ndings</term><term>Nephrol</term><term>Nephrol dial transplant</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Other countries</term><term>Polysorbate</term><term>Prca</term><term>Prca cases</term><term>Prca patients</term><term>Pure aplasia</term><term>Pure red cell aplasia</term><term>Radar group</term><term>Rare instances</term><term>Recombinant</term><term>Regulatory approval</term><term>Regulatory authorities</term><term>Roche</term><term>Rossert</term><term>Severe anemia</term><term>Singapore</term><term>Stopper</term><term>Subcutaneous</term><term>Subcutaneous administration</term><term>Subcutaneous eprex</term><term>Syringe</term><term>Transfusion</term><term>Transfusion volume</term><term>Transplant</term><term>Uncoated</term><term>Uncoated rubber stoppers</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Epoétine</term><term>Erythroblaste</term><term>Erythroblastopénie</term><term>Transfusion</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Academic investigators</term><term>Academic researchers</term><term>Adverse drug events</term><term>Alfa</term><term>Amgen</term><term>Antierythropoietin</term><term>Antierythropoietin antibodies</term><term>Aplasia</term><term>Assay</term><term>August</term><term>Beta</term><term>Canadian prca focus group</term><term>Casadevall</term><term>Cell aplasia</term><term>Chronic kidney disease</term><term>Chronic kidney disease patients</term><term>Class effect</term><term>Darbepoetin</term><term>Dial</term><term>Epoetin</term><term>Epoetin alfa</term><term>Epoetin beta</term><term>Epoetin products</term><term>Epogen</term><term>Eprex</term><term>Eprex formulation</term><term>Erythropoietin</term><term>European medicines agency</term><term>Health canada</term><term>Hematologic recovery</term><term>Hemodialysis</term><term>Hemodialysis patients</term><term>Immunosuppressive</term><term>Immunosuppressive therapy</term><term>Incidence rates</term><term>Johnson johnson</term><term>Kidney disease patients</term><term>Leachates</term><term>Mckoy</term><term>Ndings</term><term>Nephrol</term><term>Nephrol dial transplant</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Other countries</term><term>Polysorbate</term><term>Prca</term><term>Prca cases</term><term>Prca patients</term><term>Pure aplasia</term><term>Radar group</term><term>Rare instances</term><term>Recombinant</term><term>Regulatory approval</term><term>Regulatory authorities</term><term>Roche</term><term>Rossert</term><term>Severe anemia</term><term>Singapore</term><term>Stopper</term><term>Subcutaneous</term><term>Subcutaneous administration</term><term>Subcutaneous eprex</term><term>Syringe</term><term>Transfusion</term><term>Transfusion volume</term><term>Transplant</term><term>Uncoated</term><term>Uncoated rubber stoppers</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Singapour</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">BACKGROUND: Since 1988, millions of patients have received epoetin products intravenously (IV) and subcutaneously. In 1998, epoetin‐associated pure red cell aplasia (PRCA) was first reported and causation was attributed to formulations without human serum albumin (HSA), subcutaneous administration, and uncoated rubber stoppers.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Mckoy, June M" sort="Mckoy, June M" uniqKey="Mckoy J" first="June M." last="Mckoy">June M. Mckoy</name></region><name sortKey="Bennett, Charles L" sort="Bennett, Charles L" uniqKey="Bennett C" first="Charles L." last="Bennett">Charles L. Bennett</name><name sortKey="Casadevall, Nicole" sort="Casadevall, Nicole" uniqKey="Casadevall N" first="Nicole" last="Casadevall">Nicole Casadevall</name><name sortKey="Cournoyer, Denis" sort="Cournoyer, Denis" uniqKey="Cournoyer D" first="Denis" last="Cournoyer">Denis Cournoyer</name><name sortKey="Nissenson, Allen R" sort="Nissenson, Allen R" uniqKey="Nissenson A" first="Allen R." last="Nissenson">Allen R. Nissenson</name><name sortKey="Raisch, Dennis W" sort="Raisch, Dennis W" uniqKey="Raisch D" first="Dennis W." last="Raisch">Dennis W. Raisch</name><name sortKey="Rossert, Jerome" sort="Rossert, Jerome" uniqKey="Rossert J" first="Jerome" last="Rossert">Jerome Rossert</name><name sortKey="Stonecash, Robin E" sort="Stonecash, Robin E" uniqKey="Stonecash R" first="Robin E." last="Stonecash">Robin E. Stonecash</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008830 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008830 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:62C8628A4EF21823C8B13711A62B018C7EA8D332
|texte= Epoetin‐associated pure red cell aplasia: past, present, and future considerations
}}
| This area was generated with Dilib version V0.6.33. |  |